Quest Diagnostics Incorporated (DGX)
Market Cap | 20.45B |
Revenue (ttm) | 10.52B |
Net Income (ttm) | 945.00M |
Shares Out | 111.82M |
EPS (ttm) | 8.35 |
PE Ratio | 21.92 |
Forward PE | 18.31 |
Dividend | $3.20 (1.75%) |
Ex-Dividend Date | Oct 3, 2025 |
Volume | 454,075 |
Open | 183.24 |
Previous Close | 183.46 |
Day's Range | 182.51 - 185.05 |
52-Week Range | 146.17 - 185.62 |
Beta | 0.54 |
Analysts | Buy |
Price Target | 185.40 (+1.36%) |
Earnings Date | Oct 21, 2025 |
About DGX
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans,... [Read more]
Financial Performance
In 2024, Quest Diagnostics's revenue was $9.87 billion, an increase of 6.70% compared to the previous year's $9.25 billion. Earnings were $866.00 million, an increase of 1.88%.
Financial StatementsAnalyst Summary
According to 15 analysts, the average rating for DGX stock is "Buy." The 12-month stock price target is $185.4, which is an increase of 1.36% from the latest price.
News

Quest Diagnostics Incorporated (DGX) Presents At Baird Global Healthcare Conference 2025 Transcript
Quest Diagnostics Incorporated (NYSE:DGX) Baird Global Healthcare Conference 2025 September 10, 2025 10:50 AM EDT Company Participants James Davis - Chairman, CEO & President Conference Call Particip...

Quest Diagnostics Launches Advanced Pharmacogenomics (PGx) Offering
New Service Empowers Clinicians with Personalized Insights from Coriell Life Sciences to Optimize Prescribing Across Specialties SECAUCUS, N.J. , Sept. 4, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE:...

Fentanyl Positivity Is More Than Seven Times Higher in Random Tests vs. Pre-Employment Drug Screening, Finds 2025 Quest Diagnostics Drug Testing Index
Majority of fentanyl positives also contain other drugs, with co-positivity with marijuana doubling since 2020 SECAUCUS, N.J. , Sept. 2, 2025 /PRNewswire/ -- The percentage of employees in the general...

Corewell Health and Quest Diagnostics to Enter into Joint Venture Providing Enhanced Laboratory Services in Michigan
Parties to build state-of-the-art laboratory in Southfield to serve physicians and patients across the state Quest will also manage Corewell Health's 21 hospital labs SOUTHFIELD, Mich. and GRAND RAPID...

FDA Grants Breakthrough Device Designation for Haystack MRD Circulating Tumor DNA Test from Quest Diagnostics
SECAUCUS, N.J. , Aug. 25, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that the U.S. Food and Drug Administration (FDA) ha...

Quest Diagnostics to Speak at the Baird 2025 Global Healthcare Conference
SECAUCUS, N.J. , Aug. 15, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will spea...

Quest Diagnostics Declares Quarterly Cash Dividend
SECAUCUS, N.J. , Aug. 13, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today announced that its Board of Directors declared a quarterly cash dividen...

Mass General Brigham Launches Two Clinical Trials to Study Haystack MRD ctDNA as Guide for Post-surgical Treatment for Two Cancer Types
SECAUCUS, N.J. and BOSTON , Aug. 7, 2025 /PRNewswire/ -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, today announced a research collaboration with Mass General Brigham investigators at...

Quest Diagnostics Completes Acquisition of Clinical Testing Assets from Fresenius Medical Care
SECAUCUS, N.J. , Aug. 5, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced the completion of its previously announced acquisiti...

Athena Diagnostics Improves Ataxia Movement Disorder Testing with Novel Long-Read Gene Sequencing
New test utilizes technology based on PacBio's PureTarget sequencing method to uncover genetic causes of disease BOSTON , July 29, 2025 /PRNewswire/ -- Athena Diagnostics, the specialty neurology busi...

Quest Diagnostics Raises Outlook, But Warns Of Tariff And Medicare Act Risks
Quest Diagnostics Inc. DGX delivered a robust second quarter in 2025, exceeding analyst expectations with strong sales and earnings growth, prompting an upward revision to its full-year guidance.

Quest Diagnostics Incorporated (DGX) Q2 2025 Earnings Call Transcript
Quest Diagnostics Incorporated (NYSE:DGX) Q2 2025 Earnings Conference Call July 22, 2025 8:30 AM ET Company Participants James E. Davis - Chairman, CEO & President Sam A.

Quest Diagnostics raises annual forecasts on strong diagnostic testing demand
Laboratory operator Quest Diagnostics raised its 2025 profit and revenue forecasts on Tuesday, banking on robust demand for its diagnostic tests, sending the company's shares up over 3% in premarket t...

Quest Diagnostics Reports Second Quarter 2025 Financial Results; Raises Guidance for Full Year 2025
Second quarter revenues of $2.76 billion, up 15.2% from 2024 Second quarter reported diluted earnings per share ("EPS") of $2.47, up 21.7% from 2024; and adjusted diluted EPS of $2.62, up 11.5% from 2...

Quest Diagnostics Introduces Testing for Oropouche Virus
Diagnostic testing for emerging infectious disease associated with severe neurological affects SECAUCUS, N.J. , July 15, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic info...

Quest Diagnostics: Buy Into Future Patient Demand, At An Undervalued Price Today
For my initial rating of Quest Diagnostics (DGX), I'm calling it a buy. Forecasts point to continuing demand for diagnostic testing, while the company also grew its business via acquisitions and new s...

Quest Diagnostics to Offer FDA-Cleared Fujirebio Blood Test for Alzheimer's Disease
Test to be available for clinical and research use as soon as this summer, building on Quest's pioneering blood-based AD-Detect™ product line for assessing symptomatic patients SECAUCUS, N.J. , July 9...

Quest Diagnostics Releases 2024 Corporate Responsibility Report
SECAUCUS, N.J. , June 25, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today published its 2024 Corporate Responsibility Report.

Quest Diagnostics to Release Second Quarter 2025 Financial Results on July 22, 2025
SECAUCUS, N.J. , June 23, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report second quarter 2025 financial resu...

Quest Diagnostics to Develop Multi-cancer Stratification (MCaST) Blood Test Based on MD Anderson Technology
SECAUCUS, N.J. , June 10, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced a collaboration with The University of Texas MD And...

More Americans Know Their Streaming Platform Passwords by Heart Than Their Cholesterol Score, New Survey Reveals
Quest's second "Know Your Health" survey explores Americans' perceptions and priorities on their well-being in 2025 Nearly one-third of Americans say their doctors/HCPs do not take the time to discuss...

Quest Diagnostics to Speak at the William Blair 45th Annual Growth Stock Conference
SECAUCUS, N.J. , May 16, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Jim Davis, Chairman, CEO and President, will speak...

Oncologists Report Seeing More Advanced Cancers and Say Current Tests Are Not Catching Cancer Recurrence Early Enough, New Quest Diagnostics Report Finds
More than 3 in 4 oncologists (76%) feel they are seeing more advanced cancers, and of these, 75% believe that screening barriers are the leading cause, although nearly one-third (32%) cite "factors th...

Quest Diagnostics: A Leader But Waiting For Better Price
Quest Diagnostics excels in scale, scope, and service quality, leveraging automation and distribution to reduce costs and offer comprehensive test menus. Despite its strengths, I recommend waiting to ...

These Analysts Boost Their Forecasts On Quest Diagnostics After Better-Than-Expected Q1 Earnings
Quest Diagnostics Incorporated DGX posted better-than-expected first-quarter earnings on Tuesday.